TP53 and myelodysplastic syndrome: This study and others have demonstrated that TP53 mutant MDS patients share clinical and genetic features that distinguish them from patients with wild-type TP53. In addition to a higher bone marrow blast proportion, lower platelet count, and greater likelihood of having a high number of chromosomal aberrations, TP53 mutant patients relapse quickly after various forms of treatment [20, 22, 24, 45, 46].